Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Petvivo Holdings Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, PARK, HAEJIN S, who is the busiest examiner for the portfolio. The prosecution is localized within 1 distinct art unit, showing a concentrated effort in this specific field. This arrangement suggests that the company is focusing its current intellectual property strategy on a single, specific innovation within the biotech sector.
The busiest_examiner_pending count of 1 for PARK, HAEJIN S matches the total pending office actions for the company. This indicates that Petvivo Holdings Inc. is currently focused on a single patent application within the Biotechnology & Pharmaceuticals sector. The prosecution profile is highly streamlined, with all current activity managed by one examiner in one art unit. For the practitioner, this means the outcome of the company's current patent efforts depends entirely on the perspective and requirements of this specific examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARK, HAEJIN S | 1 | 55.1% | +38.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18509112 | Biocompatible Protein-Based Particles and Methods Thereof | PARK, HAEJIN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18509112 | Biocompatible Protein-Based Particles and Methods Thereof | PARK, HAEJIN S | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18509112 | Biocompatible Protein-Based Particles and Methods Thereof | PARK, HAEJIN S | 1614 | §103§112Other | Final Rejection | — | Pending | Nov 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPetvivo Holdings Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Haejin S Park has the most, with 1 of Petvivo Holdings Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
